Phathom Pharmaceuticals (PHAT) Total Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Total Liabilities data on file, last reported at $642.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 1.5% year-over-year to $642.1 million in Q1 2026; TTM through Mar 2026 was $642.1 million, a 1.5% increase from a year earlier, with the FY2025 full-year figure at $697.3 million, up 10.35% from the prior year.
• Total Liabilities for Q1 2026 stood at $642.1 million, down from $697.3 million in the prior quarter.
• Over the last five years, Total Liabilities for PHAT reached as high as $697.3 million in Q4 2025 and fell as low as $111.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $445.7 million across 5 years, with a median of $505.0 million in 2024.
• Across the five-year window, Total Liabilities soared 167.43% in 2022 and rose 1.5% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $239.6 million in 2022, then jumped by 103.07% to $486.6 million in 2023, then advanced by 29.86% to $631.9 million in 2024, then advanced by 10.35% to $697.3 million in 2025, then dropped by 7.92% to $642.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $642.1 million in Q1 2026, $697.3 million in Q4 2025, and $662.8 million in Q3 2025.